Home・Lista de Ações・Gossamer Bio Inc

Gossamer Bio Inc

Abrir

SetorSaúde

0.18 5.88

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.16

Máximo

0.18

Indicadores-chave
By Trading Economics
Rendimento	574K -47M
Vendas	3.2M 17M
EPS	-0.2
Margem de lucro	-275.223
Funcionários	161
EBITDA	2.1M -44M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+529.41% upside

Dividendos
By Acuity
Próximos Ganhos	10 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	18M 97M
Abertura anterior	-5.7
Fecho anterior	0.18

Sentimento de Notícias

By Acuity

63%

37%

285 / 340 Ranking em Healthcare

Gossamer Bio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 de ago. de 2026, 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 de jul. de 2026, 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 de jul. de 2026, 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 de jul. de 2026, 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 de jul. de 2026, 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 de jul. de 2026, 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 de jul. de 2026, 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 de jul. de 2026, 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Comparação entre Pares

Variação de preço

Gossamer Bio Inc Previsão

Preço-alvo

By TipRanks

529.41% parte superior

Previsão para 12 meses

Média 1.07 USD 529.41%

Máximo 2 USD

Mínimo 0.28 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Gossamer Bio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Gossamer Bio Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

285 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.